The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
Open accessAbstract
Protein phosphorylation is an impo-rtant cellular regulatory mechanism as many enzymes and receptors are activated/deactivated by phosphorylation and dephosphorylation events, by means of kinases and phosph-atases. In particular, the protein kinases are responsible for cellular transduction signaling and their hyperactivity, malfunction or overexpression can be found in several diseases, mostly tumors. Therefore, it is evident that the use of kinase inhibitors can be valuable for the treatment of cancer. In this review, we discuss the mechanism of action of phosphorylation, with particular attention to the importance of phosphorylation under physiological and pathological conditions. We also discuss the possibility of using kinase inhibitors in the treatment of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“This complex phosphorylates Stat1, leading to its dimerization and nuclear translocation, where it regulates gene transcription (62-65).”
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2007) · W.W. Norton eBooks · doi:10.1201/9780203833445 · Cited by 4,589
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · cited 1×
“To date, more than 1,000 variations in the expression of protein kinases have been detected in human tumors (108-111).”
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., & Mann, M. (2006) · Cell · doi:10.1016/j.cell.2006.09.026 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“…target) occurs when the drug target protein has changed due to steric hindrance to inhibitor binding (150), altered active site topography (151), disruption of favorable inhibitor interactions (152), altered protein dynamics (153), increased oncogenicity (151), and alteration of ATP affinity (154).”
Hunter, T., & Cooper, J. A. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.004341 · Cited by 2,107
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Ludwig, J. A., & Weinstein, J. N. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1739 · Cited by 1,666
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Serine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488 · cited 1×
“PPP and PMP groups are responsible for most dephosphorylation reactions of phosphoserine and phos-photreonine (pSer/pThr) and they can also dephosphorylate phosphotyrosine (pTyr) (35,36).”
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Biology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · cited 1×
“Phosphoproteomics has a critical relevance for many aspects of biology and has a significant role for understanding the molecular mechanisms, especially those that lead to the genesis and growth of tumors (77-79).”
The Age of Crosstalk: Phosphorylation, Ubiquitination, and Beyond
Hunter, T. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.019 · Cited by 942
Serine phosphorylation of STATs
Decker, T., & Kovarik, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203481 · Cited by 887
Crystal Structures of c-Src Reveal Features of Its Autoinhibitory Mechanism
Xu, W., Doshi, A., Lei, M., Eck, M. J., & Harrison, S. C. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80356-1 · Cited by 870
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C., & Thomas, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3112-3124.2004 · Cited by 742
Systematic Discovery of In Vivo Phosphorylation Networks
Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. T. M., Jørgensen, C., Miron, I. M., Diella, F., Colwill, K., Taylor, L., Elder, K., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.052 · Cited by 735
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Tyrosine phosphorylation: thirty years and counting
Hunter, T. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.028 · Cited by 658
From Promiscuity to Precision: Protein Phosphatases Get a Makeover
Virshup, D. M., & Shenolikar, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.015 · Cited by 641
Tyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 624
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Clinical proteomics: translating benchside promise into bedside reality
Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., & Liotta, L. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd891 · Cited by 550
Sefton, B. M., Hunter, T., Beemon, K., & Eckhart, W. (1980) · Cell · doi:10.1016/0092-8674(80)90327-x · Cited by 546
Pathophysiology: The Biologic Basis for Disease in Adults and Children
Fortunato, N. (1996) · AORN Journal · doi:10.1016/s0001-2092(06)63479-0 · Cited by 528
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Mathematical Models of Protein Kinase Signal Transduction
Heinrich, R., Neel, B. G., & Rapoport, T. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00528-2 · Cited by 511
Combinatorial control of the specificity of protein tyrosine phosphatases
Tonks, N. K., & Neel, B. G. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00196-4 · Cited by 501
Retinoblastoma: Clues to Human Oncogenesis
Murphree, A. L., & Benedict, W. F. (1984) · Science · doi:10.1126/science.6320372 · Cited by 496
Guan, K. L., & Dixon, J. E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47335-3 · Cited by 459
Greenlund, A. C., Farrar, M. A., Viviano, B. L., & Schreiber, R. D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06422.x · Cited by 454
Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 A resolution.
Das, A. K., Helps, N. R., Cohen, P. T., & Barford, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01071.x · Cited by 449
Linear Motif Atlas for Phosphorylation-Dependent Signaling
Miller, M. L., Jensen, L. J., Diella, F., Jørgensen, C., Tinti, M., Li, L., Hsiung, M., Parker, S. A., Bordeaux, J., Sicheritz-Ponten, T., et al. (2008) · Science Signaling · doi:10.1126/scisignal.1159433 · Cited by 442
Zhang, Z.-Y. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.083001.144616 · Cited by 433
Why nature chose phosphate to modify proteins
Hunter, T. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0013 · Cited by 430
Young, M. A., Gonfloni, S., Superti-Furga, G., Roux, B., & Kuriyan, J. (2001) · Cell · doi:10.1016/s0092-8674(01)00301-4 · Cited by 386
Molecular mechanisms of theprotein serine/threonine phosphatases
Barford, D. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10060-8 · Cited by 357
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 332
Phosphorylation in protein-protein binding: effect on stability and function
Nishi, H., Hashimoto, K., & Panchenko, A. R. (2011) · Structure · doi:10.1016/j.str.2011.09.021 · Cited by 322
Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315
Protein Phosphorylation; A Practical Approach
(1994) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(94)90074-4 · Cited by 272
Weak functional constraints on phosphoproteomes
Landry, C. R., Levy, E. D., & Michnick, S. W. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.03.003 · Cited by 272
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 263
Stehelin, D., Guntaka, R. V., Varmus, H. E., & Bishop, J. M. (1976) · Journal of Molecular Biology · doi:10.1016/0022-2836(76)90152-2 · Cited by 258
Evolution of protein phosphatases in plants and animals
Moorhead, G. B. G., De Wever, V., Templeton, G., & Kerk, D. (2009) · Biochemical Journal · doi:10.1042/bj20081986 · Cited by 254
The transcription factor Eyes absent is a protein tyrosine phosphatase
Tootle, T. L., Silver, S. J., Davies, E. L., Newman, V., Latek, R. R., Mills, I. A., Selengut, J. D., Parlikar, B. E. W., & Rebay, I. (2003) · Nature · doi:10.1038/nature02097 · Cited by 254
Rosen, O., & Erlichman, J. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40884-3 · Cited by 249
Phosphorylation of 25-kDa Synaptosome-associated Protein
Shimazaki, Y., Nishiki, T.-I., Omori, A., Sekiguchi, M., Kamata, Y., Kozaki, S., & Takahashi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.24.14548 · Cited by 246
Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy
Hainaut, P., & Plymoth, A. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b651e · Cited by 241
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., & Workman, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 239
The Chemical Biology of Protein Phosphorylation
Tarrant, M. K., & Cole, P. A. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.070907.103047 · Cited by 235
The human phosphatase interactome: An intricate family portrait
Sacco, F., Perfetto, L., Castagnoli, L., & Cesareni, G. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.008 · Cited by 233
Physicochemical mechanisms of protein regulation by phosphorylation
Nishi, H., Shaytan, A., & Panchenko, A. R. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00270 · Cited by 223
Xu, X., Sarikas, A., Dias-Santagata, D. C., Dolios, G., Lafontant, P. J., Tsai, S.-C., Zhu, W., Nakajima, H., Nakajima, H. O., Field, L. J., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.009 · Cited by 219
Igarashi, K., Garotta, G., Ozmen, L., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Larner, A. C., & Finbloom, D. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36621-8 · Cited by 218
Sundaram, M. V. (2006) · WormBook · doi:10.1895/wormbook.1.80.1 · Cited by 218
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 201
Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers
Capra, M., Nuciforo, P. G., Confalonieri, S., Quarto, M., Bianchi, M., Nebuloni, M., Boldorini, R., Pallotti, F., Viale, G., Gishizky, M. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3489 · Cited by 200
Therapeutic targets: MTOR and related pathways
Dancey, J. E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3175 · Cited by 194
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
Stegmeier, F., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 192
Harsha, H. C., & Pandey, A. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.09.004 · Cited by 178
Elucidating Human Phosphatase-Substrate Networks
Li, X., Wilmanns, M., Thornton, J., & Köhn, M. (2013) · Science Signaling · doi:10.1126/scisignal.2003203 · Cited by 171
Gentry, M. S., Dowen, R. H., Worby, C. A., Mattoo, S., Ecker, J. R., & Dixon, J. E. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704094 · Cited by 169
Hornberg, J. J., Bruggeman, F. J., Binder, B., Geest, C. R., de Vaate, A. J. M. B., Lankelma, J., Heinrich, R., & Westerhoff, H. V. (2005) · The FEBS Journal · doi:10.1111/j.1432-1033.2004.04404.x · Cited by 166
Wan, X., Shen, N., Mendoza, A., Khanna, C., & Helman, L. J. (2006) · Neoplasia · doi:10.1593/neo.05820 · Cited by 164
Modular evolution of phosphorylation-based signalling systems
Jin, J., & Pawson, T. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0106 · Cited by 163
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
Drake, J. M., Graham, N. A., Stoyanova, T., Sedghi, A., Goldstein, A. S., Cai, H., Smith, D. A., Zhang, H., Komisopoulou, E., Huang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120985109 · Cited by 159
Similar Protein Phosphatases Control Starch Metabolism in Plants and Glycogen Metabolism in Mammals
Niittylä, T., Comparot-Moss, S., Lue, W.-L., Messerli, G., Trevisan, M., Seymour, M. D. J., Gatehouse, J. A., Villadsen, D., Smith, S. M., Chen, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600519200 · Cited by 159
Construction of human activity‐based phosphorylation networks
Newman, R. H., Hu, J., Rho, H., Xie, Z., Woodard, C., Neiswinger, J., Cooper, C., Shirley, M., Clark, H. M., Hu, S., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.12 · Cited by 159
Archambault, J., Pan, G., Dahmus, G. K., Cartier, M., Marshall, N. F., Zhang, S., Dahmus, M. E., & Greenblatt, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27593 · Cited by 149
Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Non-functional phosphorylations?
Lienhard, G. E. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.05.004 · Cited by 147
Analysis of CaM-kinase Signaling in Cells
Wayman, G., Tokumitsu, H., Davare, M., & Soderling, T. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.02.007 · Cited by 129
The Molecular Perspective: The ras Oncogene
Goodsell, D. S. (1999) · Stem Cells · doi:10.1002/stem.170235 · Cited by 122
Sefton, B. M., Hunter, T. R., & Raschke, W. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1552 · Cited by 113
Levy, E. D., Michnick, S. W., & Landry, C. R. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0078 · Cited by 106
Case, N. D., Thomas, J., Sen, B., Styner, M., Xie, Z., Galior, K. D., & Rubin, J. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.265330 · Cited by 105
Wrighton, K. H., Willis, D., Long, J., Liu, F., Lin, X., & Feng, X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607246200 · Cited by 104
An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein
Hirschi, A., Cecchini, M. J., Steinhardt, R. C., Schamber, M. R., Dick, F. A., & Rubin, S. M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1868 · Cited by 103
Protein tyrosine kinases Src and Csk: a tail’s tale
Cole, P. A., Shen, K., Qiao, Y., & Wang, D. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.08.009 · Cited by 103
Javidi‐Sharifi, N., Traer, E. A., Martinez, J., Gupta, A., Taguchi, T., Dunlap, J. B., Heinrich, M. C., Corless, C. L., Rubin, B. P., Druker, B. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0573 · Cited by 99
Thingholm, T. E., Larsen, M. R., Ingrell, C. R., Kassem, M. S., & Jensen, O. N. (2008) · Journal of Proteome Research · doi:10.1021/pr800099y · Cited by 99
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 97
The Molecular Perspective: The ras Oncogene
Goodsell, D. S. (1999) · The Oncologist · doi:10.1634/theoncologist.4-3-263 · Cited by 97
CASEIN KINASE I: ANOTHER COG IN THE CIRCADIAN CLOCKWORKS
Eide, E. J., & Virshup, D. M. (2001) · Chronobiology International · doi:10.1081/cbi-100103963 · Cited by 94
Shifting paradigms: the seeds of oncogene addiction
Sawyers, C. L. (2009) · Nature Medicine · doi:10.1038/nm1009-1158 · Cited by 93
Ulivi, P., Chiadini, E., Dazzi, C., Dubini, A., Costantini, M., Medri, L., Puccetti, M., Capelli, L., Calistri, D., Verlicchi, A., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.11.004 · Cited by 92
Lafora disease: insights into neurodegeneration from plant metabolism
Gentry, M. S., Dixon, J. E., & Worby, C. A. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.08.002 · Cited by 91
Young, K., Minchom, A. R., & Larkin, J. (2012) · Future Oncology · doi:10.2217/fon.12.43 · Cited by 85
Harita, Y., Kurihara, H., Kosako, H., Tezuka, T., Sekine, T., Igarashi, T., & Hattori, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707247200 · Cited by 81
EGFR T790M resistance mutation in non small-cell lung carcinoma
Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 78
Quantitative Prediction of Fold Resistance for Inhibitors of EGFR
Balius, T. E., & Rizzo, R. C. (2009) · Biochemistry · doi:10.1021/bi900729a · Cited by 78
Ferrer, I., Blanco, R., Carmona, M., Puig, B., nguez, I. D. X. E., & Viñals, F. (2002) · Acta Neuropathologica · doi:10.1007/s00401-001-0481-9 · Cited by 76
Dixit, A., & Verkhivker, G. M. (2009) · PLoS Comput. Biol. · doi:10.1371/journal.pcbi.1000487 · Cited by 74
Targeting mTOR for Cancer Treatment
Rubio‐Viqueira, B., & Hidalgo, M. M. (2006) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-5133-3_24 · Cited by 71
Nishi, H., Fong, J. H., Chang, C., Teichmann, S. A., & Panchenko, A. R. (2013) · Molecular BioSystems · doi:10.1039/c3mb25514j · Cited by 67
Abdi, A. I., Carvalho, T. G., Wilkes, J., & Doerig, C. (2013) · Microbiology · doi:10.1099/mic.0.070409-0 · Cited by 66
Hou, S., Isaji, T., Hang, Q., Im, S., Fukuda, T., & Gu, J. (2016) · Scientific Reports · doi:10.1038/srep18430 · Cited by 63
HuPho: the human phosphatase portal
Liberti, S., Sacco, F., Calderone, A., Perfetto, L., Iannuccelli, M., Panni, S., Santonico, E., Palma, A., Nardozza, A. P., Castagnoli, L., et al. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08712.x · Cited by 62
Kataoka, M., Kuwahara, R., Iwasaki, S., Shoji‐Kasai, Y., & Takahashi, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742058.x · Cited by 59
Lee, C., Syu, S., Liu, K., Chu, P., Yang, W., Lin, P., & Shieh, W.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5640 · Cited by 55
Imatinib mesylate in the treatment of chronic myeloid leukaemia
Druker, B. J. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.963 · Cited by 54
Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer
Hasskarl, J. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-54490-3_8 · Cited by 49
Integrating phosphoproteomics in systems biology
Liu, Y., & Chance, M. R. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.07.003 · Cited by 49
Role of phosphoproteomics in the development of personalized cancer therapies
Cutillas, P. R. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400104 · Cited by 44
Carvajal‐Hausdorf, D., Schalper, K. A., Pusztai, L., Psyrri, A. K., Kalogeras, K. T., Kotoula, V., Fountzilas, G., & Rimm, D. L. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv136 · Cited by 38
Paladino, D., Yue, P., Furuya, H., Acoba, J. D., Rosser, C. J., & Turkson, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6635 · Cited by 38
Li, Z., Lin, P., Gao, C., Peng, C., Liu, S., Gao, H., Wang, B., Wang, J., Niu, J., & Niu, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-4353-7 · Cited by 34
Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance
Murray, B. W., & Miller, N. L. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0088 · Cited by 29
Salazar, C., & Höfer, T. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.093 · Cited by 28
Kraus, J., Kraus, M., Liu, N., Bešše, L., Bader, J. E., Geurink, P. P., de Bruin, G., Kisselev, A. F., Overkleeft, H. S., & Driessen, C. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2801-0 · Cited by 27
Ahmadian, M. R. (2002) · British Journal of Haematology · doi:10.1046/j.0007-1048.2001.03314.x · Cited by 26
Personalized Network-Based Treatments in Oncology
Robin, X., Creixell, P., Radetskaya, O., Santini, C. C., Longden, J., & Linding, R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.171 · Cited by 25
Aita, Y., Ishii, K., Saito, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00156.2012 · Cited by 24
Phosphoproteomics‐based network medicine
Liu, Z., Wang, Y., & Xue, Y. (2013) · FEBS Journal · doi:10.1111/febs.12380 · Cited by 23
The STE group kinase SepA controls cleavage furrow formation in Dictyostelium
Müller‐Taubenberger, A., Ishikawa-Ankerhold, H. C., Kastner, P. M., Burghardt, E., & Gerisch, G. (2009) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20386 · Cited by 23
From c-src to v-src, or the case of the missing C terminus.
Sefton, B. M., & Hunter, T. (1986) · PubMed · Cited by 22
HUPHO: the human phosphatase portal
Liberti, S., Calderone, A., Sacco, F., Perfetto, L., Iannuccelli, M., Panni, S., Santonico, E., Palma, A., Nardozza, A. P., Castagnoli, L., et al. (2012) · EMBnet journal · doi:10.14806/ej.18.a.380 · Cited by 18
PTP-central: A comprehensive resource of protein tyrosine phosphatases in eukaryotic genomes
Hatzihristidis, T., Liu, S., Pryszcz, L. P., Hutchins, A. P., Gabaldón, T., Tremblay, M. L., & Miranda‐Saavedra, D. (2013) · Methods · doi:10.1016/j.ymeth.2013.07.031 · Cited by 17
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer
Czarnecka, A. M., Solarek, W., Kornakiewicz, A., & Szczylik, C. A. (2015) · Oncology Reports · doi:10.3892/or.2015.4514 · Cited by 16
Mehraein‐Ghomi, F., Church, D. R., Schreiber, C. L., Weichmann, A. M. M., Basu, H. S., & Wilding, G. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.77 · Cited by 15
Sharma, A., Tan, T. H., Cheetham, G., Scott, H. S., & Brown, M. P. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825134ac · Cited by 14
ABDURAHMAN, A., Anwar, J., Turghun, A., Niyaz, M., Zhang, L., & Awut, I. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.564 · Cited by 14
Zhu, N., Xiao, H., Wang, L., Fu, S., Zhao, C., & Huang, H. (2015) · Future Oncology · doi:10.2217/fon.14.280 · Cited by 12
Lankheet, N. A. G., Huitema, A. D. R., Mallo, H. A., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1579-4 · Cited by 10
Axelsson, J., Rippe, A., & Rippe, B. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00632.2014 · Cited by 6
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Alquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367
Mehta, M., Dhanjal, D. S., Paudel, K. R., Singh, B., Gupta, G., Rajeshkumar, S., Thangavelu, L., Tambuwala, M. M., Bakshi, H. A., Chellappan, D. K., et al. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00698-3 · Cited by 330
Metadata
- Authors
- Ardito, F., Giuliani, M., Perrone, D., Troiano, G., & Muzio, L. L.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2017-06-22
- Volume
- 40
- Issue
- 2
- Pages
- 271-280
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W2635415917
- Cited by
- 1,336
- References
- 152
- FWCI
- 23.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.